Value of lipid accumulation product for the assessment of metabolic syndrome in women with polycystic ovary syndrome

Antic Ivana Bozic; Jelica Bjekic-Macut; Dimitrios Panidis; Danijela Vojnovic Milutinovic; Biljana Kastratovic; Milan Petakov; Bojana Popovic; Sanja Ognjanovic; Tamara Bogavac; Tatjana Isailovic; Valentina Elezovic; Dusan Ilic; Djuro Macut

doi:10.1530/endoabs.32.P588

P588

Prev Next

Section Contents Cite

Endocrine Abstracts (2013) 32 P588 | DOI: 10.1530/endoabs.32.P588

ECE2013 Poster Presentations Female reproduction (47 abstracts)

Value of lipid accumulation product for the assessment of metabolic syndrome in women with polycystic ovary syndrome

Ivana Bozic Antic ¹ , Jelica Bjekic-Macut ² , Dimitrios Panidis ³ , Danijela Vojnovic Milutinovic ⁴ , Biljana Kastratovic ⁵ , Milan Petakov ¹ , Bojana Popovic ¹ , Sanja Ognjanovic ¹ , Tamara Bogavac ¹ , Tatjana Isailovic ¹ , Valentina Elezovic ¹ , Dusan Ilic ¹ & Djuro Macut ¹

Err

Author affiliations

¹Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; ²Clinical-Hospital Center “Bežanijska kosa”, Belgrade, Serbia; ³Division of Endocrinology and Human Reproduction, 2nd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece; ⁴Institute for Biologic Investigations ”Siniša Stanković“, Belgrade, Serbia; ⁵Clinic for Obstetrics and Gynecology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Introduction: Women with polycystic ovary syndrome (PCOS) have higher prevalence of metabolic syndrome (MS) than healthy, age and BMI matched women. The aim of this study was to determine if novel abdominal adiposity index – lipid accumulation product (LAP), could predict MS in women with PCOS.

Methods: PCOS was diagnosed using ESHRE/ASRM criteria. We evaluated 218 non-obese PCOS women (PCOS group: 22.4±3.6 kg/m²; 24.8±4.6 years) and 44 non-obese, BMI-matched healthy women (control group: 21.3±3.2 kg/m²; 28.4±4.9 years). MS was diagnosed according to JIS criteria (waist circumference cut off 80 cm) in 29/218 (13%) PCOS women, while no woman in controls group had MS. PCOS group was divided into subgroups: PCOS with MS (27.3±2.8 kg/m²; 27.4±6.2 years) and PCOS without MS (21.6±3.0 kg/m²; 24.3±4.2 years). In all subjects blood pressure (BP) and waist circumference (WC) were determined. Blood samples were collected in follicular phase of menstrual cycle for determination of basal glucose, insulin, HDL-cholesterol, triglycerides, testosterone, SHBG and DHEAS. Systolic and diastolic BP (SBP and DBP, respectively) were determined. LAP was calculated using formula ((WC-58)×triglycerides). Homeostatic model (HOMA) index and free androgen index (FAI) were also calculated using standard formula.

Results: There was no difference in LAP between PCOS and controls (20.4±19.3 vs 18.2±23.5, P=0.27). PCOS without MS had significantly lower LAP than PCOS with MS (15.4±12.4 vs 51.6±26.2, P<0.001) and there was no difference in LAP between PCOS without MS and controls (P=0.56). In PCOS group LAP correlated with HOMA (r=0.29, P<0.001), FAI (r=0.40, P<0.001), SBP (r=0.26, P<0.001), DBP (r=0.23, P<0.001). JIS criteria for MS, FAI and LAP entered binary logistic regression analysis which showed that independent predictors for MS in PCOS group were LAP (P=0.002), SBP (P=0.001) and HDL-cholesterol (P=0.001).